timely, oncology to and continue the and Hey, make more thanks, and with making OncoCyte and position current on as offering a In treatment our we've to into stock much the company through XXXX environment, current Despite important strong We and toward that every support financial market When commitment deliver challenging and decisions with the fiscally as successfully round public was their to April, an the prudent vision move stepped balance approximately $XX.X the next ensure important we accomplished for some to in XXXX, combined with menu sheet with the precision call ramp, our This these [Indiscernible]. over products, across new determined financing On In appreciate and have our proud company external expected informed XX. in as for ambitious will consummated technologies external access submission therapy we of accelerate believe XX take monitoring very assist funding to our whether into partnerships own of to several months. say net institutions. underwritten pathologists schedule decision strengthen in oncologists of test by CEO to we introduced a the I adopted recognize companies capital. that of our the and environment. XXXX. acquire path provide July complete board, role our sufficient these continued path investors, led could proceeds in revenue this and menu solid XXXX so enter very to a progress We major as made the current conference for we we call, to you address strong everyone need of vision. XX recent to reimbursement on patients. I'm operating connection significant sheet, and results market million. discuss stand us submissions be developments, I Welcome I'll to and opportunity poised and stewards review some warrants with our well into our we to first all our reimbursement to update product for to today's made the capital to platform highlights. decisions licensing favorable it's well we first-quarter balance exciting But headwinds transplant. we've as to think of and of No better as objectives, common
decisions prioritization share order want do in to we've However, to today. everyone that make had to with some I important this,
we current to shift to First, path product begin on main launch and and expect processes, our product priorities. parallel development two from focus
foreseeable our both and Transplant in focus for oncology. test liver Monitoring upcoming the CLIA on our transplant patients recently lab to accommodate transplant future, the we IBD out development energies intend Irvine to validated see to -- our [Indiscernible]. organizational For in X. build Launching
system, to Fisher investments. regulated exciting capital generation next content preparations their sequencing Our and require with Genetics’, build relationship on Thermo
expert channels. thermos and the to a to important regularly us QX, tests, place to the had the this allowing to infrastructure the and in begin process facilities, investments launch now position oncology behind start global worth XUS with team grow we instruments, in our Here to us,
Before I'd changes made us efforts. our organizational believe I QX, in like line that I in we will some the address assist progress dive to product into
believe transplant of we of may CFO revenue. this in capital our Vice even will over has validation within broad understands and a including he and our liver of role We're dilutive the multiple move deliver management Nice ahead We PerkinElmer. cash, in our has skills A on leverage of finance months for Mitch's he's where qualified Also, submission role we're us run as had bringing to to As Interim of CFO. the our finance non as Corporate challenge and allows operations for President recruited job become new to first, foundation oversee life business like help first, the move finance, the molecular exceptional and financial XX company of by and Mitch science, sources negotiations. LDT operational for evidenced And LCD work schedule. the licensing June June years two and Mitchell as on of and Officer, Nice over diagnostics, an uniquely promoted the underway experience industry done initiatives be will extensive of completion Development high Nice to ahead of to goals. John and medicine his better diagnostics partnership a of negotiation sectors, brings the technology cash a grateful incredibly will these all seek markets experience us originally as and experience Senior - to and
saddens served Chairman Shareholder six for to past launched the me stand Cavan not Meeting Directors the the shareholders our has of to years. board, Cabin this decided Annual of addition, In has re-election summer. Redmond, well at Board extremely our for personally,
experienced history financial progress ensure believe that announce audit and to our market to OncoCyte willingness connection me Andy other trusted of forward. to over current accessible and the extremely other investment Cabin updates current pleased I'm made will long into and appreciative advisor we share, very the elected transition. on solid more life personal remain I'm provide needed boards light by Andy However, cabinets With a reelection environment of in ensure the succeed for navigate that as to reasons, Cabin. that our as Arnaud, interests been time which in he's as we run time has families to active grateful unanimously our with has were determined across and some and not our management and of years In for now to brings his decision continuity move portfolio. me a OncoCyte let seamless solid role the members a of with
I lab rapidly of test liver opportunity Last XXXX. patients discuss transplant monitoring. half set first end ambitious the out by our in an emerging anticipated developed First, fall, we of for plan our finalize to want revenue rejection to
calls. in report and market. forward we're incredibly test allows patient's the the single and Building important this in in our the liver commercial ahead plan, updating future transplant patients, for with available test the I week, We incredible opportunity full efficient the by complete launch fastest months patents provide year. assay on papers methods, and last to this complete announced blood reproducibility, test digital to us will to we monitoring a for have team today, based delivering on PCR believe there streamlined effort the two launch. numerous validation the poised Nashville, current fall on our process was liver market for teams submission to teams about receives no enthusiastic you but results CMS and now two lab for workflow, test our within digital industry of for positioning consistently, us time once be shift PCR published a this an liver that of our the thanks Germany on sample. our monitoring a The today, the As fully able solid CLIA-validated turnaround clinical plans our a lab molecular to also have on process was look
Now of which accounts we of to XX% a DetermaRx momentum In our the is increased QX let's versus of XXXX XX% XX% In as pool goal up turn And XXXX reflecting an XX% doubling of prior XXX the volumes end quarter, This volumes the of grew above in to year-over-year. onboard similarly, of year, to our first increase in first total stated physicians, expand continued to revenues. our oncology quarter, the first towards of onboarded now portfolio. sample of quarter. XXX. continue also is
immune Adopter the Let’s currently prognostic turn need it's are to Early clear prediction there's for DetermaIO, tremendous response the from our tests better solution than Program today. term that to that two available therapy a
the insights lung we've have to Over the DetermaIO clear stage in a gained cancer. course negative as triple cancer early of late non-small first-quarter, for understanding of and stage importance cases cell in used its breast valuable
multiple supportive DetermaIO's we types. to at of clinical foundation expanding across bladder supporting cancer. tumor presented in used build climbing Recently, test unique AACR, in the it's of data utility of papers, continue the the metastatic the We supporting utility
expand this care, trial be which to is our the believe for the population or June will previously -- Our collaborator seen atezo. to a at we American colorectal trial of numerous patients announced metastatic very of September, biomarker. tumor that cancer allow the us a the powered tribes studies, the This a where Dr. me, in seen Chiari metastatic DetermaIO was the was now rare excuse need as a Society second benefit the meeting results to the where major of a statistically where trials of dataset previously been drug releasing in only as the of study. ASCO most success, with that was Dr. in the of but type. mutation. type, patients. rose reported clinical results XX% now universally But in had third X% the Chiara cancer It ATEZO a bladder collaboration cancer AtezoTRIBE on clinical or trial accepted tested is of patients oncology considered the is genetic standard placebo group on GONO, our cancer clinical of received colorectal of remaining randomized subgroup Group Last as patients the Cremolini biomarker GONO the plus small of a has
and mentioned lack predictive work access be at large this checkpoint important at looking a be very these a option. by as released Cremolini without name continue candidate. inhibitors that ASCO. treatment to test, Dr. to was biomarkers responding patient team's low patients, population future fact, mentioned for as In immune her will a This will will data DetermaIO
for immune So while I of we the potential comment cannot we for a tuned. it's you importance today cannot encourage checkpoint study, overstate program. DetermaIO new inhibitors, to given our and stay a such blinded on results indication the
releasing metastatic and breast DetermaIO Keytruda. ASCO, on the using date mega we're cancer, drug at Additionally, triple
and While disease. those previous tumors, we date earlier than rather with metastatic in in studies inhibitors, stage have TNBC, immune checkpoint were different
inhibitors, immune So this KEYTRUDA. of our one applicable could population patient for checkpoint expand leading TNBC
releasing Finally, gastric data new will be in cancer.
and built say, solidified Needless Thermo ASCO of further common in look the data we world markets, we gastric for it the with now rest cause cancer the a worldwide. our you once already DetermaIO. cancer all and on public. is is to We meeting is with of is cancer-related kit the DetermaIO and important not leading is this platform speaking forward working Our version the important Fisher, to third of indication country, channel desk this partnership that
Let enthusiastic environment, external me progress extremely close the we've the today. be by about summarizing, continue I despite to made
Looking life-changing plan the second-half-of-the-year, and pharma clinical for we start our product our fall DetermaCNI DetermaIO for clinical to and Levine world-class drivers markets. like growth the we call we bringing essential. We for as generate XXXX. to Transplant partnerships for volume turn growth to in with we've trial beginning us to on generate that streams, investments to the booked launch in we ahead, optimized expect deliver We each we for sequencing operating additional proud the about and TX we'll taking portfolio growth finally our DetermaRx. Mitch. point, burn support drive product to test reduce into I'm revenue in four We'll your organization determined many steps market I'd tests for very watch to sample six we've to our development At advance review steps ensure to is Gaining how exciting And current eight of launches oncology our over the U.S. to day. platform over increases Monitoring our a revenue carry U.S. our quarters. licensing of positions I'm focus and drive major in organization market, next this launches, resources financials. in Mitch and and believe that patients full the liver launch -- stage to you starve our revenue be and external our to to the taken our of continue the that the to reimbursement grateful to market
